Edgewise Therapeutics (NASDAQ:EWTX) is a pioneering firm focused on leveraging precision medicine to address a range of serious musculoskeletal diseases with a primary focus on Duchenne and Becker muscular dystrophies. At the heart of its operations, Edgewise Therapeutics is deeply involved in discovering, developing, and deploying transformative therapies designed to improve the lives of individuals grappling with these challenging conditions. Through a robust pipeline of therapeutic candidates, the company aims to halt muscle damage, reduce the severity of symptoms, and ultimately enhance quality of life. With a steadfast commitment to innovation and patient health, Edgewise Therapeutics sets the bar in redefining treatment standards for musculoskeletal diseases, underpinned by rigorous research, strategic collaborations, and a patient-centric approach.